^
Association details:
| Biomarker: | MYCN amplification |
|---|---|
| Cancer: | Neuroblastoma |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) + erbumine (LY3295668) (Aurora kinase A inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
2006 / 10 - Preclinical evaluation of dual AURKA (LY3295668) and BCL2 (venetoclax) inhibition in neuroblastoma (NB)
Published date:
03/09/2022
Excerpt:
LY3295668 (30mg/kg) and venetoclax (50mg/kg)...when administered in combination showed a maximum weight loss of 13%....Four of five MYCN-amplified PDX models demonstrated maintained complete responses and one showed significant tumor growth delay….Dual targeting of AURKA and BCL2 with LY3295668 and venetoclax is tolerable and demonstrates compelling anti-tumor activity in MYCN-amplified NB PDX models...
